Curat Global LLC Has $782,000 Stake in Merck & Co., Inc. $MRK

Curat Global LLC trimmed its stake in Merck & Co., Inc. (NYSE:MRK) by 39.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 7,427 shares of the company’s stock after selling 4,760 shares during the period. Merck & Co., Inc. accounts for about 0.9% of Curat Global LLC’s holdings, making the stock its 25th largest position. Curat Global LLC’s holdings in Merck & Co., Inc. were worth $782,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Heritage Investors Management Corp grew its position in Merck & Co., Inc. by 0.7% in the 4th quarter. Heritage Investors Management Corp now owns 331,872 shares of the company’s stock worth $34,933,000 after purchasing an additional 2,211 shares during the last quarter. Resolute Wealth Strategies LLC lifted its holdings in shares of Merck & Co., Inc. by 14.6% during the 4th quarter. Resolute Wealth Strategies LLC now owns 7,045 shares of the company’s stock worth $742,000 after acquiring an additional 897 shares during the period. Bare Financial Services Inc lifted its holdings in shares of Merck & Co., Inc. by 214.7% during the 4th quarter. Bare Financial Services Inc now owns 1,158 shares of the company’s stock worth $122,000 after acquiring an additional 790 shares during the period. Hexagon Capital Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 5.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 15,252 shares of the company’s stock worth $1,606,000 after acquiring an additional 762 shares during the period. Finally, Global Retirement Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 110.4% during the 4th quarter. Global Retirement Partners LLC now owns 87,713 shares of the company’s stock worth $9,233,000 after acquiring an additional 46,016 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $115.86 on Friday. The stock has a 50-day simple moving average of $115.79 and a 200 day simple moving average of $110.13. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12-month low of $75.40 and a 12-month high of $125.14. The stock has a market capitalization of $286.15 billion, a price-to-earnings ratio of 32.64, a P/E/G ratio of 2.54 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on MRK shares. Wells Fargo & Company reduced their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a report on Friday, May 1st. JPMorgan Chase & Co. raised their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Barclays started coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They set an “overweight” rating and a $140.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Sichuan Kelun-Biotech said their lung cancer combination therapy met the main goal in a late-stage China trial, improving survival in patients with advanced lung cancer and adding to confidence in Merck’s Keytruda-based oncology franchise. Article Title
• Positive Sentiment: Merck and Moderna reported five-year data showing their skin-cancer combination therapy cut the risk of cancer spreading by 59% in a mid-stage melanoma study, reinforcing the commercial potential of Merck’s immuno-oncology pipeline. Article Title
• Positive Sentiment: Exelixis announced a collaboration with Merck on a late-stage colorectal cancer study, signaling continued pipeline expansion and more shots on goal in oncology. Article Title
• Neutral Sentiment: A market roundup highlighted Merck among dividend stocks to consider, but the piece was broad and did not provide company-specific catalysts. Article Title
• Negative Sentiment: A separate article from Zacks argued that Eli Lilly looks stronger than Merck due to Lilly’s GLP-1 momentum and pipeline, which could weigh on sentiment versus MRK’s peers. Article Title
• Negative Sentiment: Merck Animal Health was referred to the FTC and FDA over Bravecto Quantum dosing claims after not complying with an advertising review recommendation, creating a regulatory/reputation overhang for the animal-health business. Article Title

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.